No insider purchase over the last 90 days. The latest, by Baller Lance, was filed 14 Jan 2026.
Every trade that managers of Global Healthcare REIT, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. Over the twelve months to 22 October 2026, 1 filing were filed, from 1 insider.
Every open-market trade in the period is a purchase: 1 purchase worth €12k, from 1 insider, and not a single sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 senior executive among the declarants. Biggest ticket of the year: €12k, bought by Baller Lance and made public on 14 January 2026.
With 1 filing in twelve months, the company is quieter than the median of 8 filings across the 277 companies we follow on the same exchange. The full history, which starts in 2016, counts 17 purchases against no sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 41.4 m USD and net income at -1.0 m USD.
The latest purchase dates back some time: it was published 283 days ago, on 14 January 2026.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2025 · cache
25 of 67 declarations
Global Healthcare REIT, Inc. is a real estate investment trust focused on acquiring and managing properties in the healthcare sector. It is listed on the NASDAQ under the symbol GHC.
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2025 | 41.4 m USD | -1.0 m USD | -0.34 USD | 10-K |
| Dec 2024 | 39.5 m USD | -2.4 m USD | -0.80 USD | 10-K |
| Dec 2023 | 36.8 m USD | -4.0 m USD | -1.31 USD | 10-K |
| Dec 2022 | 40.6 m USD | -2.4 m USD | -0.79 USD | 10-K/A |
| Dec 2021 | 29.3 m USD | -2.3 m USD | -0.82 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.